| Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know |
Rapt Therapeutics (RAPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-05-16 17:01:14 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Reports First Quarter 2025 Financial Results |
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development |
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D. |
globenewswire.com |
2025-04-15 12:00:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics to Participate in Upcoming Investor Conferences |
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: |
globenewswire.com |
2025-03-07 18:30:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results |
SOUTH SAN FRANCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”) is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the fourth quarter and year ended December 31, 2024. |
globenewswire.com |
2025-03-06 10:00:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy |
Rapt Therapeutics (RAPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-10 15:01:18 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time. |
globenewswire.com |
2025-01-09 10:00:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors |
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. |
globenewswire.com |
2025-01-06 10:00:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Announces $150 Million Private Placement |
SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing novel therapies for patients with significant unmet needs in inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 100,000,000 shares of common stock at a purchase price of $0.85 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 76,452,000 shares of common stock at a price per pre-funded warrant of $0.8499, for gross proceeds of approximately $150.0 million. The private placement is expected to close on or about December 27, 2024, subject to the satisfaction of customary closing conditions. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock, be immediately exercisable and remain exercisable until exercised in full. |
globenewswire.com |
2024-12-23 09:10:00 |
Czytaj oryginał (ang.) |
| Rapt Therapeutics Stock Plummets, Terminates Asthma Trial Due To Patient's Liver Injury |
On Monday, Rapt Therapeutics, Inc. RAPT stock is trading lower after the company announced it was terminating its zelnecirnon (RPT193) program. |
benzinga.com |
2024-11-11 12:34:20 |
Czytaj oryginał (ang.) |
| Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround |
Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-06-14 14:36:21 |
Czytaj oryginał (ang.) |
| Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-05-29 14:35:26 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity |
RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Liver failure in a single patient with a complex medical history resulted in a clinical hold by the FDA, leaving RAPT no choice but to unblind both ongoing ph2 studies. The probability that zelnecirnon caused the hepatic failure is low considering alternative explanations and no prior preclinical/clinical evidence of liver toxicity. |
seekingalpha.com |
2024-05-20 08:35:23 |
Czytaj oryginał (ang.) |
| Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks |
The heavy selling pressure might have exhausted for Rapt Therapeutics (RAPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-05-13 14:36:07 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Reports First Quarter 2024 Financial Results |
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2024. |
globenewswire.com |
2024-05-09 12:00:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients |
- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in subset of patients with HPV+ disease - Median duration of treatment in responders was 19.6 months at the time of data cutoff SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced). |
globenewswire.com |
2024-04-09 16:00:00 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks to Dump Before They Go to Zero |
It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason. |
investorplace.com |
2024-04-09 10:31:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT |
NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-03-11 20:06:00 |
Czytaj oryginał (ang.) |
| Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? |
RAPT Therapeutics (RAPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
zacks.com |
2024-03-07 11:41:04 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results |
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2023. |
globenewswire.com |
2024-03-07 10:00:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting |
Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer |
globenewswire.com |
2024-03-05 18:30:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT |
NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2024-03-03 12:15:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings |
NEW YORK--(BUSINESS WIRE)---- $RAPT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. (“RAPT” or “the Company”) (NASDAQ: RAPT). Investors who purchased RAPT securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RAPT. Investigation Details: On February 20, 2024, RAPT issued a press release “announc[ing] that the U.S. Food and Drug Admini. |
businesswire.com |
2024-02-26 06:00:00 |
Czytaj oryginał (ang.) |
| Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests |
Biotech stock Rapt plummeted to a record low Tuesday after the Food and Drug Administration put two of its clinical studies on hold. |
investors.com |
2024-02-20 14:14:28 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics' stock plunges as FDA halts two clinical trials |
RAPT Therapeutics Inc. shares RAPT, +1.68% dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation treatment due to liver failure in a trial participant. |
marketwatch.com |
2024-02-20 10:36:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon |
- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company's Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. |
globenewswire.com |
2024-02-20 09:30:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations |
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations. |
globenewswire.com |
2024-02-13 10:00:00 |
Czytaj oryginał (ang.) |
| RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference |
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 2:00 p.m. ET . |
globenewswire.com |
2024-01-31 10:00:00 |
Czytaj oryginał (ang.) |